SCALED MICROBIOMICS, LLC

Biotech · Private

IgY immunotherapeutic formulation (egg-derived antibodies against human norovirus strains)

Grants
$300K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · An immunotherapeutic IgY formulation against norovirus diarrhea$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1947RAKTA THERAPEUTICS, INC.——
1948IGF Oncology, LLC—$2.4M
1949GENECENTRIX INC.——
1950SCALED MICROBIOMICS, LLC——
1951RYLTI, LLC—$2.3M
1952Cargo Therapeutics—$69M
1953Plex Pharmaceuticals, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 8
  • Treating Or Preventing Travelers Diarrheaapplication
  • Systems And Methods For Altering Microbiome To Reduce Disease Risk And Manifestations Of Diseaseapplication
  • Formulations For Altering Microbiome To Reduce Risks Of Hereditary And Spontaneous Colorectal Cancersapplication
  • Treating Or Preventing Travelers Diarrheaapplication
  • Formulations For Altering Microbiome To Reduce Risks Of Familial Adenomatous Polyposis And Colorectal Cancersapplication
  • Systems And Methods For Altering Microbiome To Reduce Disease Risk And Manifestations Of Diseaseapplication
  • Systems And Methods For Altering Microbiome To Reduce Disease Risk And Manifestations Of Diseaseapplication
  • Treating Or Preventing Travelers Diarrheaapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.